160 patients diagnosed with multiple sclerosis (MS) were randomly assigned to receive either cannabis-based medicinal extracts (CMBE), a mixture of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), or placebo through oromucosal spray for 6 weeks. Patients were assessed on the change in VAS score of their nominated primary symptom (PSS), time in seconds to walk 10m, and various other cognitive functioning tests. Results demonstrated that CMBE was effective in reducing symptoms in patients who nominated spasticity as their primary symptom, but did not significantly differ from placebo in reducing symptoms in patients who nominated spasm, bladder control, pain, and tremor as their primary symptom.